ChartMill assigns a fundamental rating of 4 / 10 to KERX.
ChartMill assigns a valuation rating of 0 / 10 to Keryx Biopharmaceuticals (KERX). This can be considered as Overvalued.
Keryx Biopharmaceuticals (KERX) has a profitability rating of 3 / 10.
The dividend rating of Keryx Biopharmaceuticals (KERX) is 0 / 10 and the dividend payout ratio is 0%.